Adjuvant Effects of Fermented Red Ginseng Extract on Advanced Non-Small Cell Lung Cancer Patients Treated with Chemotherapy

被引:0
作者
JIANG Shu-long [1 ,2 ]
LIU Hong-jie [3 ]
LIU Zhao-chun [4 ]
LIU Ning [2 ]
LIU Rui [1 ]
Young-Reep Kang [5 ]
Joong-Gu Ji [6 ]
ZHANG Chao [7 ]
HUA Bao-jin [1 ]
Shin-Jyung Kang [8 ]
机构
[1] Department of Oncology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences
[2] Department of Oncology,Jining First People's Hospital
[3] School of Medicine,Jinan University
[4] Institute of International Education,Shandong University of Traditional Chinese Medicine
[5] Industry-Academic Cooperation Foundation (IACF),Joongbu University
[6] Department of Oriental Health Care,Joongbu University
[7] Department of Stomatology,Jining First People's Hospital
[8] Department of Herbal Pharmaceutical Science,Joongbu University
关键词
lung cancer; Korean red ginseng; fermented red ginseng extract; chemotoxicity; tumor adjuvant therapy; Chinese medicine;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
Objective: To investigate the adjuvant therapeutic effects of fermented red ginseng(FRG) extract on non-small cell lung cancer(NSCLC) patients treated with chemotherapy. Methods: A total of 60 patients with advanced NSCLC were assigned to two groups using a random number table, i.e., the gemcitabine plus cisplatin(GP) chemotherapy alone group(26 patients) and the FRG + GP chemotherapy group(34 patients), for 60-day treatment. Patients were then assessed according to the Fatigue Symptom Inventory, Chinese medicine symptoms score, Self-Rating Anxiety Scale, Self-Rating Depression Scale, Karnofsky Performance Status Scale, and Functional Assessment of Cancer Therapy-Lung. In addition, chemotherapy toxicity and tumor biomarkers were measured. Results: For NSCLC patients after chemotherapy, FRG extract significantly improved the FSI score, CM symptoms score, psychological status, physical conditions, and quality of life and reduced chemotherapy toxicity(P<0.01), but the expression levels of carcinoembryonic antigen, cytokeratin-19 fragments, and neuron-specific enolase were not significantly different between the chemotherapy alone and the FRG + chemotherapy groups or between pre-and post-treatments(P>0.05). Conclusions: This study demonstrated that FRG extract had an adjuvant effect on advanced NSCLC patients treated with chemotherapy. Further studies with a larger sample size will verify the current findings.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 50 条
  • [41] Radiographic features of pneumonitis in patients treated with immunotherapy compared to traditional chemotherapy for non-small cell lung cancer
    Capaccione, Kathleen M.
    Huang, Sophia
    D'souza, Belinda
    Leb, Jay
    Luk, Lyndon
    Goldstein, Jonathan
    May, Benjamin
    Deng, Aileen
    Salvatore, Mary M.
    CLINICAL IMAGING, 2023, 93 : 106 - 112
  • [42] The use of immunotherapy in older patients with advanced non-small cell lung cancer
    Tagliamento, Marco
    Frelaut, Maxime
    Baldini, Capucine
    Naigeon, Marie
    Nencioni, Alessio
    Chaput, Nathalie
    Besse, Benjamin
    CANCER TREATMENT REVIEWS, 2022, 106
  • [43] Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
    Zhao, Dan
    Mambetsariev, Isa
    Li, Haiqing
    Chen, Chen
    Fricke, Jeremy
    Fann, Patricia
    Kulkarni, Prakash
    Xing, Yan
    Lee, Peter P.
    Bild, Andrea
    Massarelli, Erminia
    Koczywas, Marianna
    Reckamp, Karen
    Salgia, Ravi
    LUNG CANCER, 2020, 146 : 174 - 181
  • [44] Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer
    Hamilton, Gerhard
    Olszewski, Ulrike
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (10) : 1381 - 1390
  • [45] Principles of induction chemotherapy for non-small cell lung cancer
    Jablonka, S
    Furmanik, F
    Jablonka, A
    Paprota, K
    Karczmarek-Borowska, B
    Kukielka-Budny, B
    Korobowicz, E
    Zdunek, M
    Sagan, D
    LUNG CANCER, 2001, 34 : S151 - S153
  • [46] Chemotherapy in non-small cell lung cancer: opportunities for advancement
    Akhtari, Mani
    Bernicker, Eric H.
    Teh, Bin S.
    CHINESE JOURNAL OF CANCER, 2016, 35 : 56
  • [47] Adjuvant chemotherapy of non-small cell lung cancer: Tolerance of combined cisplatin-pemetrexed therapy
    Gauvain, C.
    Crequit, P.
    Rousseau-Bussac, G.
    Ganoun, A.
    Baud, M.
    Chouaid, C.
    REVUE DES MALADIES RESPIRATOIRES, 2014, 31 (09) : 817 - 821
  • [48] Time to adjuvant chemotherapy and survival in non-small cell lung cancer A Population-Based Study
    Booth, Christopher M.
    Shepherd, Frances A.
    Peng, Yingwei
    Darling, Gail
    Li, Gavin
    Kong, Weidong
    Biagi, James J.
    Mackillop, William J.
    CANCER, 2013, 119 (06) : 1243 - 1250
  • [49] Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer
    Cucevic, B
    Samarzija, M
    Baricevic, D
    Jakopovic, M
    Redzepi, G
    Samija, M
    COLLEGIUM ANTROPOLOGICUM, 2005, 29 (02) : 583 - 588
  • [50] Radiation Dose Painting with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer
    Wang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E500 - E501